To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Infections in patients with multiple sclerosis: A national cohort study in Sweden
Real-world Insights, IQVIA Nordics, Solna, Sweden.
Real-world Insights, IQVIA Nordics, Solna, Sweden.
Real-world Insights, IQVIA Nordics, Solna, Sweden.
Real-world Insights, IQVIA Nordics, Solna, Sweden.
Show others and affiliations
2020 (English)In: Multiple Sclerosis and Related Disorders, ISSN 2211-0348, E-ISSN 2211-0356, Vol. 45, article id 102420Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Multiple sclerosis (MS) patients have an increased risk of infections, but few population-based studies have reported infections occurring in MS in the years immediately after diagnosis.

OBJECTIVE: To explore incident infections in MS, stratified by age and sex.

METHODS: In a Swedish population-based cohort study 6602 incident MS patients (aged ≥18 years), matched at diagnosis with 61,828 matched MS-free individuals were identified between 1st January 2008 and 31st December 2016, using national registers. Incidence rates (IR) and incidence rate ratios (IRR) with 95% CI were calculated for each outcome.

RESULTS: The IRRs were 2.54 (95% CI 2.28-2.83) for first serious infection and 1.61 (1.52-1.71) for first non-serious infection. Compared with MS-free individuals, MS patients had higher IRs for skin, respiratory/throat infections, pneumonia/influenza, bacterial, viral, and fungal infections, with the highest IRR observed for urinary tract/kidney infections (2.44; 2.24-2.66). The cumulative incidence for most of these infections was higher among MS patients than MS-free individuals, both 0 to <5 and 5 to <9 years after index date.

CONCLUSION: The burden of infections around the time of MS diagnosis and subsequent infection risk, underscore the need for careful considerations regarding the risk-benefit across different disease-modifying therapies.

Place, publisher, year, edition, pages
Elsevier, 2020. Vol. 45, article id 102420
Keywords [en]
Cohort study, Comorbidities, Health registers, Incidence, Infections, Multiple sclerosis
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-84776DOI: 10.1016/j.msard.2020.102420ISI: 000582230900066PubMedID: 32736217Scopus ID: 2-s2.0-85088664874OAI: oai:DiVA.org:oru-84776DiVA, id: diva2:1463918
Note

Funding Agency:

IQVIA

Available from: 2020-09-03 Created: 2020-09-03 Last updated: 2020-11-11Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Montgomery, Scott

Search in DiVA

By author/editor
Montgomery, Scott
By organisation
School of Medical Sciences
In the same journal
Multiple Sclerosis and Related Disorders
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 201 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf